Why Elanco?
We have entered a new era of sustainable growth. The animal health industry is projected to add approximately $20 billion in value over the next decade, and Elanco is uniquely positioned to lead in this durable, high-growth market. With the successful launch of our Big 6 innovation portfolio, we are now advancing our Next Wave pipeline, targeting 5–6 new blockbusters by 2031 and unlocking more than $2 billion in peak sales potential. Through Elanco Ascend, we expect to drive meaningful margin expansion and operational efficiency beginning in 2026, with a commitment to deliver more than $1 billion in free cash flow through 2028 and reduce net leverage below 3x by 2027. Our strategic focus on growth, innovation and cash is driven by consistent execution and record engagement from our teams - building on more than 70 years of leadership in transforming animal health to create long-term value for customers, communities and shareholders.
Press Releases
